Abhishek Ghosh, Akshayee Kale, Raj Laxmi, Shalini S Naik, B N Subodh, Debasish Basu
{"title":"Breaking barriers: Assessing the feasibility and acceptability of telemedicine-assisted buprenorphine induction for opioid use disorder in India.","authors":"Abhishek Ghosh, Akshayee Kale, Raj Laxmi, Shalini S Naik, B N Subodh, Debasish Basu","doi":"10.4103/indianjpsychiatry.indianjpsychiatry_432_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Telemedicine-assisted buprenorphine (BNX) induction (TABI) has the potential to reduce the treatment gap for opioid use disorder.</p><p><strong>Aim: </strong>This study investigated the acceptability and feasibility of TABI in India. This was a retrospective study from a specialized addiction treatment center in a teaching hospital.</p><p><strong>Methods: </strong>TABI was introduced in November 2022; patients enrolled till May 2023 were included in the analysis. Feasibility was assessed by the proportion of patients who completed the TABI program, continued treatment for at least 3 months, and self-reported nonprescription opioid use during and after TABI. Acceptability was measured by patient satisfaction with TABI.</p><p><strong>Results: </strong>Sixty patients were enrolled: Fifty-three patients (88.3%) were retained during the TABI program, and 50 patients (83.3%) remained in treatment at the 3-month follow-up. Thirty-five patients (58.3%) reported using nonprescription opioids during TABI, and 28 patients (46.7%) reported such use after completing the program. Thirty-five (58.3%) were satisfied with the program, and 15 (25%) said they would recommend it to others. Patients who missed scheduled in-person appointments (<i>P</i> < .001) at 1 week, did not return unused BNX-naloxone (<i>P</i> < .001), and were not satisfied (<i>P</i> = .004) were more likely to report nonprescription opioid use. Those who attended the in-person follow-up at 1 week (<i>P</i> = .004) and were satisfied (<i>P</i> = .01) and did not use nonprescription opioids either during (<i>P</i> = .003) or after (<i>P</i> < .001) TABI were more likely to be retained in treatment at 3 months.</p><p><strong>Conclusion: </strong>The study shows TABI's acceptability and feasibility in a specialized addiction treatment setting; further research is needed for broader applicability.</p>","PeriodicalId":13345,"journal":{"name":"Indian Journal of Psychiatry","volume":"66 10","pages":"956-962"},"PeriodicalIF":1.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633259/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_432_24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Telemedicine-assisted buprenorphine (BNX) induction (TABI) has the potential to reduce the treatment gap for opioid use disorder.
Aim: This study investigated the acceptability and feasibility of TABI in India. This was a retrospective study from a specialized addiction treatment center in a teaching hospital.
Methods: TABI was introduced in November 2022; patients enrolled till May 2023 were included in the analysis. Feasibility was assessed by the proportion of patients who completed the TABI program, continued treatment for at least 3 months, and self-reported nonprescription opioid use during and after TABI. Acceptability was measured by patient satisfaction with TABI.
Results: Sixty patients were enrolled: Fifty-three patients (88.3%) were retained during the TABI program, and 50 patients (83.3%) remained in treatment at the 3-month follow-up. Thirty-five patients (58.3%) reported using nonprescription opioids during TABI, and 28 patients (46.7%) reported such use after completing the program. Thirty-five (58.3%) were satisfied with the program, and 15 (25%) said they would recommend it to others. Patients who missed scheduled in-person appointments (P < .001) at 1 week, did not return unused BNX-naloxone (P < .001), and were not satisfied (P = .004) were more likely to report nonprescription opioid use. Those who attended the in-person follow-up at 1 week (P = .004) and were satisfied (P = .01) and did not use nonprescription opioids either during (P = .003) or after (P < .001) TABI were more likely to be retained in treatment at 3 months.
Conclusion: The study shows TABI's acceptability and feasibility in a specialized addiction treatment setting; further research is needed for broader applicability.
期刊介绍：
The Indian Journal of Psychiatry (ISSN 0019-5545), is an official publication of the Indian Psychiatric Society. It is published Bimonthly with one additional supplement (total 5 issues). The IJP publishes original work in all the fields of psychiatry. All papers are peer-reviewed before publication.
The issues are published Bimonthly. An additional supplement is also published annually. Articles can be submitted online from www.journalonweb.com . The journal provides immediate free access to all the published articles. The journal does not charge the authors for submission, processing or publication of the articles.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
